Combined Treatment of Esophageal Vein Rupture Bleeding with Phentolamine and Pituitary Posterior Lobe Hormone February 17, 1995

Combined Treatment of Esophageal Vein Rupture Bleeding with Phentolamine and Pituitary Posterior Lobe Hormone February 17, 1995

<!-- translated-chunk:23/63 -->

Pituitrin is a potent vasoconstrictor with significant constrictive effects on the splenic artery and mesenteric artery, thereby reducing bleeding in the portal system. To date, no other drug can replace it in the treatment of ruptured esophageal variceal bleeding. The liver tissue contains a large number of α receptors, and phentolamine is an important α receptor antagonist that strongly counteracts the effects of adrenaline, causing dilation of peripheral blood vessels and capillaries within the hepatic sinusoids, thus reducing peripheral vascular resistance. In particular, it can dilate the portal vein, thereby lowering portal venous pressure. Phentolamine 20 mg is added to 500 mL of 10% glucose, and Pituitrin 20 U is added to 500 mL of 10% glucose, administered via dual-channel infusion. The infusion rate of Pituitrin is 0.3–0.6 U per minute, while the infusion rate of phentolamine is generally 50–80 µg per minute.